Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment

Figure 1

BKT130 reduces CD11b+ cell migration to the laser-treated area. Rat retinal flat mounts were prepared 10 days following laser injury and intravitreal injections. Flat mounts were observed using a confocal laser scanning system. CD11b-positive cells were observed in the center of the laser-treated areas (a). Each laser-treated area was observed in a 40x lens, and the macrophages (magenta) were counted (b–e). The eyes injected with BKT130, aflibercept, or BKT130+aflibercept demonstrated less CD11b-positive cells ((d) and (e), respectively) compared with PBS-injected eyes (b). A comparison between the amounts of cells found in laser-treated areas in each group is provided in (f). The -axis presents the mean (±SEM) number of CD11b+ cells found in each laser-treated area, in either BKT130 (number of laser ), aflibercept ( laser injury areas), BKT130+aflibercept (), or control PBS-injected group (). and .